Pfizer, Astellas end Caduet agreement in Japan; Novartis' Ultibro tops Advair in COPD study;

> Pfizer Japan and Astellas Pharma have agreed to terminate the Japanese distribution and copromotion agreement for Caduet combo tablets at the end of next March. Report

> New data shows that Novartis' ($NVS) once-daily Ultibro Breezhaler was superior in reducing COPD flare-ups compared with GlaxoSmithKline's ($GSK) Seretide, known as Advair in the U.S. Release

> ThromboGenics' Jetrea has won approval in South Korea. Release

> Mylan ($MYL) will acquire the U.S. rights to DVT drug Arixtra from Aspen. Release

> An FDA advisory committee has recommended against approval of Actavis' ($ACT) Nebivolol/Valsartan fixed-dose combination NDA for the treatment of hypertension. Release

> Omnicom's Adelphi Worldwide has purchased healthcare brand and research agency The Planning Shop international. Story

> Johnson & Johnson ($JNJ) Vision Care is offering a new range of promotional materials designed to help opticians attract, convert and retain contact lens patients. More

And Finally... AmerisourceBergen's ($ABC) new ad campaign uses a mirror concept to illustrate how the company creates a unified brand. More

Suggested Articles

Eli Lilly bought full-page ads in more than a dozen newspapers in the U.S. to let people with diabetes who use Lilly drugs to know help is available.

Only months after a game-changing new approval for Vascepa, Amarin has lost a key fight over its patents—and now it's scrambling to respond.

Move over, Roche. There’s a new small cell lung cancer therapy on the scene, and it belongs to AstraZeneca.